In vitro activity of novel rifamycins against gram-positive clinical isolates.
We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.
Murphy
Christopher K
CK
ActivBiotics, Inc., Lexington, MA 02421, USA. drothstein@activbiotics.com
Karginova
Elena
E
Sahm
Dan
D
Rothstein
David M
DM
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004347:Drug Interactions; D013293:Enterococcus faecalis / Q000187:drug effects; D016984:Enterococcus faecium / Q000187:drug effects; D006095:Gram-Positive Cocci / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013292:Streptococcus agalactiae / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
D000900:Anti-Bacterial Agents; D012294:Rifamycins; D003577:Cytochrome P-450 Enzyme System